GlassScriptPhysician profile
Daniel L Arellano
NPI 1346552437
$8,050.00
in general payments reported to CMS, 2019-2025
29 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,615 · 2022: $1,681 · 2023: $1,501 · 2024: $1,374 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,753.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $1,996.60 | 2021-2025 | Giapreza, Zevtera |
| Abbvie INC. | $1,039.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $696.79 | 2021-2024 | Andexxa |
| Merck Sharp & Dohme LLC | $370.64 | 2023-2025 | Zerbaxa, Recarbrio |
| Amgen INC. | $323.16 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $279.49 | 2022 | |
| Abiomed | $269.83 | 2021-2025 | |
| Alcresta Therapeutics, INC. | $245.91 | 2024-2025 | Relizorb |
| Mallinckrodt Hospital Products INC. | $235.91 | 2023-2025 | Terlivaz |
| Abbott Laboratories | $232.54 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Shionogi INC | $219.84 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $217.60 | 2021-2025 | Opsumit, Uptravi |
| Btg International INC. | $172.26 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $152.48 | 2023 | Rebyota |
| Genentech USA, INC. | $141.47 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $121.86 | 2025 | Livdelzi |
| Genzyme Corporation | $121.52 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $120.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.94 | 2023 | Reblozyl |
| Philips North America LLC | $117.84 | 2024 | (1439) Hpm Undivided |
| Kiniksa Pharmaceuticals International, Plc | $116.29 | 2024 | Arcalyst |
| Dova Pharmaceuticals | $112.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $106.94 | 2025 | Recorlev |
| Janssen Biotech, INC. | $106.82 | 2021 | |
| Melinta Therapeutics, LLC | $105.46 | 2025 | Vabomere, Kimyrsa, Minocin |
| Horizon Therapeutics Plc | $99.84 | 2022 | |
| Fisher & Paykel Healthcare INC | $72.11 | 2021 | |
| Biogen, INC. | $68.61 | 2023 | |
| Celgene Corporation | $66.54 | 2025 | Breyanzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arellano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.